GlassScriptPhysician profile
Michael J Moffett
NPI 1407803083
$9,680.46
in general payments reported to CMS, 2019-2025
45 companies · $360 in 2025
The $360 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,524 · 2020: $1,028 · 2021: $615 · 2022: $156 · 2023: $353 · 2024: $644 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,084 · Education: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,084.28 |
| Education | $273.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tesaro, INC. | $4,286.04 | 2019 | |
| Exelixis INC. | $944.18 | 2019-2025 | Cabometyx |
| Secura Bio, INC. | $615.28 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $526.23 | 2019-2021 | |
| Pfizer INC. | $321.18 | 2019-2025 | |
| Abbvie INC. | $303.31 | 2019-2024 | |
| Daiichi Sankyo INC. | $303.16 | 2019-2025 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $271.47 | 2019-2025 | Lynparza |
| Merck Sharp & Dohme LLC | $265.90 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $199.41 | 2019-2020 | |
| Octapharma USA, INC. | $152.21 | 2019 | |
| Janssen Biotech, INC. | $118.67 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $117.78 | 2019 | |
| Amgen INC. | $108.71 | 2019 | |
| Alexion Pharmaceuticals, INC. | $89.95 | 2019-2020 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Moffett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.